LONDON (Reuters) – London’s High Court on Tuesday ruled that one of Moderna’s patents relating to technology key to the development of vaccines for COVID-19 was invalid, but that another was valid and had been infringed by Pfizer and BioNTech’s rival vaccine. Pfizer and its German partner BioNTech sued Moderna at London’s High Court in […]
Moderna (MRNA) stock tumbled Wednesday after the company said its newly approved RSV vaccine was only about 50% effective after 18 months — paling in comparison to rivals from Pfizer (PFE) and GSK (GSK). ↑ X NOW PLAYING CRSP Stock On Wild Ride After FDA’s Historic Approval. These Gene Editing Treatments Could Come Next. Respiratory […]
Moderna’s late-stage trial for its COVID-flu combination vaccine yielded positive results, the pharmaceutical and biotechnology company announced Monday. The combination vaccine, which Moderna calls mRNA-1083, produced a higher immune response than standalone vaccines for COVID-19 or influenza. The results were also seen among trail participants 65 years and older, whom often don’t show as strong […]
Some investors might view Moderna (NASDAQ: MRNA) as a shooting star that shined bright for a while then flamed out. In 2022, the biotech company generated sales of nearly $18.9 billion, but it expects revenue of only $4 billion this year. The real story for Moderna is much better than that steep sales decline reflects. […]
By Patrick Wingrove (Reuters) – Moderna said on Monday its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response in adults aged 50 and over when compared to separate shots against the viruses in a late-stage trial. In the study, the combination using messenger RNA technology generated greater antibodies than […]
Moderna (NASDAQ: MRNA) jumped into the limelight when it started developing a coronavirus vaccine candidate. And the stock soared as the vaccine raced across the finish line and went on to bring in billions of dollars in earnings. But in later pandemic days, investors started worrying about Moderna’s dependence on its only commercialized product, and […]
Moderna (MRNA) stock sank Friday after the Food and Drug Administration approved its RSV vaccine, dubbed mResvia, allowing the biotech giant to launch its second-ever product.
Moderna (NASDAQ: MRNA) isn’t new to artificial intelligence (AI). The biotech best known for its billion-dollar coronavirus vaccine has been using this hot technology for years to help it save crucial time in the laboratory. For example, Moderna uses AI to produce mRNAs for researchers to work with, so they no longer have to create […]
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) over the Covid-19 vaccine. The EPO’s Opposition Division upheld the validity of one of Moderna’s crucial patents, boosting the mRNA vaccine maker’s […]
(Reuters) -Moderna has won a case at the European Patent Office against Pfizer and BioNTech in a dispute over its COVID-19 vaccine, the company said on Friday. Moderna said that the European Patent Office had decided to maintain the validity of one of the company’s key patents currently asserted against Pfizer and BioNTech in various […]
Novavax (NASDAQ: NVAX) and Moderna (NASDAQ: MRNA) both entered the coronavirus vaccine race around the same time, in early pandemic days, and their shares soared — in fact, Novavax rose the most, gaining 2,700% in 2020 compared to a 400% increase for Moderna. Investors were betting on the companies’ coronavirus vaccine candidates and their ability […]
By Patrick Wingrove (Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher. Sales of Moderna’s COVID-19 shot Spikevax, its only marketed product, dropped 91% from the previous year to $167 million for the quarter but surpassed […]